|Dr. Hermann Luebbert Ph.D.||Chairman, CEO & President||476.36k||N/A||1956|
|Mr. Eugene Frederick Leffler III||Chief Financial Officer||316.32k||N/A||1985|
|Ms. Erica F. Gates CPA, M.B.A.||Senior Director of Finance & Principal Accounting Officer||N/A||N/A||N/A|
|Mr. Jon Lyons M.B.A., Ph.D.||Vice President of Scientific & Medical Affairs||N/A||N/A||N/A|
|Ms. Alycia Torres||Vice President of Administration||N/A||N/A||N/A|
|Mr. Daniel Hakansson J.D.||General Counsel & Head of Compliance||N/A||N/A||N/A|
|Ms. Samantha Widdicombe||Senior Director of Strategic Accounts & Communications||N/A||N/A||N/A|
|Mr. Mark Baldyga||Vice President of & Marketing||N/A||N/A||N/A|
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Biofrontera Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.